Multifactorial analysis of exchanger efficiency and liquid conservation during perfluorochemical liquid-assisted ventilation. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Multifactorial analysis of exchanger efficiency and liquid conservation during perfluorochemical liquid-assisted ventilation.

Biomed Instrum Technol. 1999 May-Jun;33(3):260-7. Unique Identifier : AIDSLINE MED/99288488
Wolfson MR; Miller TF; Peck G; Shaffer TH; Department of Physiology, Temple University School of Medicine,; Philadelphia, Pennsylvania 19140, USA.; marlar@astro.ocis.temple.edu

Abstract: Liquid-assisted ventilation (LAV) of the lung with perfluorochemical (PFC) requires a method of oxygenating and removing CO2 from the liquid. Current PFC LAV techniques consist of total liquid ventilation, PFC lavage, and partial liquid ventilation. Because PFC liquid is volatile, it may be lost from the lung or ventilator circuit in the expired gas. This study evaluated the efficiencies of two types of exchangers (spray bubbler and membrane oxygenator) with respect to CO2 elimination from the PFC liquid and prevention of the loss of PFC liquid. A multifactorial analysis of exchanger efficiency was performed with respect to liquid conservation and CO2 removal. PFC losses and relative efficiencies of two types of exchangers to eliminate CO2 from expired PFC liquid were evaluated, along with two types of PFC liquids. Gas (100% O2 at 4 and 8 L/min) and PFC liquid were circulated countercurrently through the exchangers (oxygenator and bubbler) through a temperature-controlled (25 degrees or 37 degrees C) open circuit. To evaluate effectiveness of CO2 elimination, an exchanger efficiency index (EEI) for CO2 was calculated applying mass-transfer theory to characterize gas transport down a concentration gradient where EEI equals: [PPFCCO2 out--PPFCCO2 in]/PgasCO2 in--PPFCCO2 in]. Rate of PFC loss from the circuit was calculated from mixed expired gas samples using a thermal detector analyzer. EEI and PFC loss rate were analyzed with respect to gas: PFC liquid flow ratios (analogous to the V/Q ratio). The results showed that 1) PFC loss rate and exchanger efficiency to remove CO2 increased with increasing gas: PFC liquid flow rates independent of the type of exchanger or PFC liquid; 2) PFC loss rate at any gas or liquid flow rate was greater for the bubbler than for the oxygenator; 3) the oxygenator was more efficient than the bubbler with respect to CO2 elimination; 4) although PFC loss rate increased with temperature and vapor pressure, there was little difference in the EEIs for the temperatures studied. These results 1) identify exchanger requirements necessary to maintain effective CO2 elimination up to four times normal CO2 loading conditions during LAV; 2) suggest that using a membrane oxygenator as the gas exchanger, in concert with stringent fluid temperature control, improves PFC liquid conservation and CO2 elimination relative to bubbler exchanger configurations; 3) highlight the importance of matching the exchanger type to the physiocochemical properties of the specific PFC liquid to optimize CO2 elimination while reducing PFC liquid loss by minimizing gas relative to PFC liquid flow rates. Because PFC liquid loss occurs with all current means of oxygenating and removing CO2, this study raises the importance of developing alternative, bulk-gas-flow-independent, means to recondition PFC liquids.
Keywords: JOURNAL ARTICLE Carbon Dioxide/METABOLISM Emulsions/*ADMINISTRATION & DOSAGE Equipment Design Evaluation Studies Extracorporeal Membrane Oxygenation Fluorocarbons/*ADMINISTRATION & DOSAGE/ANALYSIS/CHEMISTRY Human Pressure Pulmonary Gas Exchange Respiration, Artificial/INSTRUMENTATION/*METHODS Support, Non-U.S. Gov'tKWDjournalarticlecarbondioxide/metabolismemulsions/KWDadministration&dosageequipmentdesignevaluationstudiesextracorporealmembraneoxygenationfluorocarbons/KWDadministration&dosage/analysis/chemistryhumanpressurepulmonarygasexchangerespiration,artificial/instrumentation/KWDmethodssupport,non-uKWDsKWDgov't
991030
A99A0939

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .